Cytotherapies in multiple myeloma: a complementary approach to current treatments?

Bibliography

• Trounson A, Thakar RG, Lomax G, et al. Clinical trials for stem cell therapies. BMC Med 2011;9:1-7
   PubMedGoogle Scholar
• Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360(25):2645-54
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Lavazza C, Di Nicola C, et al. Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2006;17(12):1225-40
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23(7):879-94
   PubMed Web of Science ®Google Scholar
• Lavazza C, Carlo-Stella C, Giacomini A, et al. Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 2010;115(11):2231-40
   PubMed Web of Science ®Google Scholar
• Corsten MF, Shah K. Therapeutic stem cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol 2008;9(4):376-84
   PubMed Web of Science ®Google Scholar
• Ciavarella S, Dominici M, Dammacco F, et al. Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev 2011;20(1):1-10
   PubMed Web of Science ®Google Scholar
• Dawson MR, Chae SS, Jain RK, et al. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am J Cancer Res 2011;1:144-54
   Web of Science ®Google Scholar
• Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Rev 2006;25(4):521-9
   PubMed Web of Science ®Google Scholar
• Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007;28(5):219-26
   PubMed Web of Science ®Google Scholar
• Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007;21:1079-88
   PubMed Web of Science ®Google Scholar
• Li X, Ling W, Pennisi A, et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cell 2011;29:263-73
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36
   PubMed Web of Science ®Google Scholar
• Karp JM, LengTeo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4(3):206-16
   PubMed Web of Science ®Google Scholar
• Mahmud N, Pang W, Cobbs C, et al. Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model. Exp Hematol 2004;32(5):494-501
   PubMed Web of Science ®Google Scholar
• Meira LB, Bugni JM, Grren SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008;118(7):2516-25
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
   PubMed Web of Science ®Google Scholar
• Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15(10):730-8
   PubMed Web of Science ®Google Scholar
• Cao Y, Luetkens T, Kobold S, et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010;38(10):860-7
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2011;357:539-45
   Google Scholar
• Li X, Ling W, Khan S, et al. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res 2012;27(8):1635-48
   PubMed Web of Science ®Google Scholar
• Xu S, Menu E, De Becker A, et al. Bone Marrow Derived Mesenchymal Stromal Cells are Attracted by Multiple Myeloma Cell-Produced Chemokine CCL25 and Favor Myeloma Cell Growth In Vitro and In Vivo. Stem Cells 2011;30(2):266-79
   Web of Science ®Google Scholar
• Ciavarella S, Grisendi G, Dominici M, et al. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol 2012;157:586-98
   PubMed Web of Science ®Google Scholar
• Sartoris S, Mazzocco M, Tinelli M, et al. Efficacy Assessment of Interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model. Stem Cells Dev 2011;20(4):709-19
   PubMed Web of Science ®Google Scholar
• Son BR, Marquez-Curtis LA, Kucia M, et al. Migration of bone marrow and cord blood mesenchymal stem cells invitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-64
   PubMed Web of Science ®Google Scholar
• Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010;116:2519-30
   PubMed Web of Science ®Google Scholar
• Segers VFM, VanRiet I, Andries LJ, et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am J Physiol Heart Circ Physiol 2006;290:1370-7
   PubMed Web of Science ®Google Scholar
• Li Y, Yu X, Lin S, et al. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem Biophys Res Commun 2007;356:780-4
   PubMed Web of Science ®Google Scholar
• Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009;27:2614-23
   PubMed Web of Science ®Google Scholar
• Van Valckenborgh E, Mincher D, Di Salvo A, et al. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia 2005;19:1628-33
   PubMed Web of Science ®Google Scholar
• Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997;90(4):1649-55
   PubMed Web of Science ®Google Scholar
• Valckenborgh EV, Asosingh K, Van Riet I, et al. Matrix metalloproteinases in multiple myeloma. Cancer Ther 2004;2:29-38
   Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Chauhan D, et al. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992;80:2306-14
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-20
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82
   PubMed Web of Science ®Google Scholar
• Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006;6:93-106
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Bai M, Margaritis D, et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res 2010;30:2831-6
   PubMed Web of Science ®Google Scholar
• Martin SK, Diamond P, Gronthos S, et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011;25:1533-42
   PubMed Web of Science ®Google Scholar
• Colla S, Storti P, Donofrio G, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 2010;24:1967-70
   PubMed Web of Science ®Google Scholar
• Winner M, Koong AC, Rendon BE, et al. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res 2007;67:186-93
   PubMed Web of Science ®Google Scholar
• Noll JE, Williams SA, Purton LE, et al. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J 2012;2(9):1-10
   Google Scholar
• Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012;120(1):20-30
   PubMed Web of Science ®Google Scholar
• Wallace SR, Oken MM, Lunetta KL, et al. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001;91:1219-30
   PubMed Web of Science ®Google Scholar
• Zdzisinska B, Bojarska-Junak A, Dmoszynska A, et al. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 2008;56:207-21
   PubMed Web of Science ®Google Scholar
• Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996;88(6):2219-27
   PubMed Web of Science ®Google Scholar
• Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011;52:1787-94
   PubMed Web of Science ®Google Scholar
• Olson DL, Burkly LC, Leone DR, et al. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005;4:91-9
   PubMed Web of Science ®Google Scholar
• Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113(18):4341-51
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24
   PubMed Web of Science ®Google Scholar
• Tucci M, De Palma R, Lombardi L, et al. Beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 2009;69(16):6738-46
   PubMed Web of Science ®Google Scholar
• Azab AK, Quang P, Azab F, et al. P-selectinglyco-protein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2012;119(6):1468-78
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117(14):3720-32
   PubMed Web of Science ®Google Scholar
• Zdzisinska B, Bojarska-Junak A, Dmoszynska A, et al. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 2008;56:207-21
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35
   PubMed Web of Science ®Google Scholar
• Studeny M, Marini FC, Champlin RE, et al. Bone marrow derived mesenchymal stem cells as vehicles for interferon β delivery into tumors. Cancer Res 2002;62:3603-8
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271(22):12687-90
   PubMed Web of Science ®Google Scholar
• Liabakk NB, Sundan A, Torp S, et al. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 2002;259:119-28
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104(2):155-62
   PubMed Web of Science ®Google Scholar
• Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337-48
   PubMed Web of Science ®Google Scholar
• Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood–derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-23
   PubMed Web of Science ®Google Scholar
• Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing STRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27:2320-30
   PubMed Web of Science ®Google Scholar
• Mohr A, Lyons M, Deedigan L, et al. Mesenchymal stem cells expressing TRAIL lead to tumor growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008;12:2628-43
   PubMed Web of Science ®Google Scholar
• Grisendi G, Bussoalri R, Cafarelli L, et al. Adipose derived mesenchymal stromal stem cells as stable source of tumor necrosis factor related apoptosis inducing ligant delivery for cancer therapy. Cancer Res 2010;67:1307-14
   Google Scholar
• Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic application. Blood 2001;98:795-804
   PubMed Web of Science ®Google Scholar
• Balsas P, López-Royuela N, Galán-Malo S, et al. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 2009;77:804-12
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Pati S, Anderson S A, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006;203:1235-47
   PubMed Web of Science ®Google Scholar
• Xu WT, Bian ZY, Fan QM, et al. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett 2009;281:32-41
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006;80:267-74
   PubMed Web of Science ®Google Scholar
• Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009;4:4992
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M, Munsell MF, et al. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004;103:1815-22
   PubMed Web of Science ®Google Scholar
• Sun B, Roh K H, Park J R, et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy 2009;11:289-98
   Web of Science ®Google Scholar
• De Vos J, Hose D, Reme T, et al. Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 2006;210:86-104
   PubMed Web of Science ®Google Scholar
• Reagan MR, Ghobrial IM. Multiple Myeloma Mesenchymal Stem Cells: characterization, Origin, and Tumor-Promoting Effects. Clin Cancer Res 2012;15(18):342
   Google Scholar
• Markovina S, Callander NS, O'Connor SL, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer 2010;9:176
   PubMed Web of Science ®Google Scholar
• Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010;12:R210
   PubMed Web of Science ®Google Scholar
• Ichim TE, Alexandrescu DT, Solano F, et al. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol 2010;260:75-82
   PubMed Web of Science ®Google Scholar
• Luz-Crawford P, Noel D, Fernandez X, et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. J Transl Med 2012;10(3):P16
   PubMedGoogle Scholar
• Wagner W. Implications of long-term culture for mesenchymal stem cells: genetic defects or epigenetic regulation? Stem Cell Res Ther 2012;3(6):54
   PubMedGoogle Scholar